EMVision Medical Devices (ASX:EMV) shipped an emu brain scanner to a second US pivotal validation trial site, the Mayo Clinic in Jacksonville, Florida, according to a Monday Australian bourse filing.
The site initiation visit and training are scheduled to begin in early May, the filing said.
The site initiation visit and device training visit at its first US site, the University of Texas Health Science Center at Houston Medical School and Memorial Hermann-Texas Medical Center, is scheduled for this week.
The primary goal of the trial is to demonstrate haemorrhage detection sensitivity and specificity of greater than 80%, supporting the device's registration with the US Food and Drug Administration.
It plans to initiate further trial sites in the US and Australia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.